DataMeds AI, Inc. to acquire Helomics Corporation

DataMeds AI, Inc. has agreed to acquire Helomics Corporation in a strategic acquisition within the technology sector. The transaction was announced on 15 September 2026 and completed four days earlier on 11 September 2026. Both parties are based in the United States. The deal structure involves consideration through shares and loan notes. No financial value for the transaction was disclosed to the public, and the specific currency is not reported. This arrangement allows DataMeds AI to integrate Helomics’ capabilities into its existing operations without revealing the monetary terms of the agreement.

The acquisition marks a significant step for both companies in consolidating their positions within the US technology market. By utilising shares and loan notes as consideration, the parties have structured the deal to align long-term interests while maintaining flexibility in capital allocation. The completion date precedes the announcement date, indicating that operational integration likely began before public disclosure. This timing is not uncommon in strategic transactions where regulatory or internal approvals must be finalised prior to media release. The transaction has been completed successfully. The companies are now proceeding with post-merger integration activities as planned.